Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19

To read the full story

• Sign In
• Subscribe

Related Article

• Deciphera Portfolio Powers Ono to Record Sales as It Eyes Post-Opdivo Era
  May 11, 2026

• Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
  October 31, 2025

• Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
  May 9, 2025

• Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
  November 1, 2024

• Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
  May 10, 2024

• Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
  November 2, 2023

• Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
  August 1, 2023

• Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
  May 11, 2023

• Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
  May 11, 2023

• Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales
  February 1, 2023

• Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
  November 1, 2022

• Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
  August 2, 2022

• Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
  May 12, 2022

• Buoyant Opdivo and Forxiga Drive Ono’s Growth in April-December
  February 1, 2022

• Ono Enjoys Double-Digit Growth in H1 on Upbeat Opdivo, Forxiga
  November 2, 2021

• Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
  May 12, 2021

• Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
  February 2, 2021

• Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
  May 13, 2020